Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma by Ilyas Sahin, Yawara Kawano, Romanos.

Slides:



Advertisements
Similar presentations
Volume 81, Issue 11, Pages (June 2012)
Advertisements

Bmi-1 Is Essential for the Tumorigenicity of Neuroblastoma Cells
Aldehyde Dehydrogenase 1A1 Possesses Stem-Like Properties and Predicts Lung Cancer Patient Outcome  Xiao Li, MD, Liyan Wan, MD, Jian Geng, MD, Chin-Lee.
Elevated FOXC2 Expression Promotes Invasion of HCC Cell Lines and is Associated with Poor Prognosis in Hepatocellular Carcinoma Cell Physiol Biochem 2017;44:99–109.
Hypoxia increases IL-32 expression in an HIF1α-dependent manner.
Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss by Muhammad Zahoor, Marita Westhrin,
Volume 15, Issue 6, Pages (June 2009)
Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation  Michael Weber,
SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy
Fig. 1. TP is highly expressed in myeloma.
by Benjamin J. Frisch, John M. Ashton, Lianping Xing, Michael W
Cell Surface CD74–MIF Interactions Drive Melanoma Survival in Response to Interferon-γ  Keiji Tanese, Yuuri Hashimoto, Zuzana Berkova, Yuling Wang, Felipe.
Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival by Kai-Da Wu, Lisa.
Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells by Toshihiko Tanno, Yiting Lim, Qiuju.
Jasmine George, Minakshi Nihal, Chandra K
Volume 81, Issue 11, Pages (June 2012)
by Alexis S. Bailey, Shuguang Jiang, Michael Afentoulis, Christina I
Yongping Shao, Kaitlyn Le, Hanyin Cheng, Andrew E. Aplin 
Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia by Xue-Fei Huang, Shao-Kai Luo,
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf–mediated interactions with bone marrow stromal cells by Yu-Tzu.
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.
Myung Jin Son, Kevin Woolard, Do-Hyun Nam, Jeongwu Lee, Howard A. Fine 
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition by.
Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy by Mark P. Chao, Chad Tang, Russell K. Pachynski,
Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists by Christopher T.
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma by Aldo M. Roccaro, Antonio.
Silencing of Discoidin Domain Receptor-1 (DDR1) Concurrently Inhibits Multiple Steps of Metastasis Cascade in Gastric Cancer  Ryo Yuge, Yasuhiko Kitadai,
Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies by Katrin U. Lundin, Peter O.
Attenuated MDSC-suppressive activity and metastasis development in IDO-deficient mice is rescued by IL-6. Attenuated MDSC-suppressive activity and metastasis.
Aldehyde Dehydrogenase 1A1 Possesses Stem-Like Properties and Predicts Lung Cancer Patient Outcome  Xiao Li, MD, Liyan Wan, MD, Jian Geng, MD, Chin-Lee.
CCN2 Expression by Tumor Stroma Is Required for Melanoma Metastasis
Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone.
Pak2 regulates myeloid-derived suppressor cell development in mice
Antisense Oligonucleotides Targeting Y-Box Binding Protein-1 Inhibit Tumor Angiogenesis by Downregulating Bcl-xL-VEGFR2/-Tie Axes  Kiyoko Setoguchi, Lin.
Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference by Eva Ortega-Paino, Johan Fransson, Sara Ek,
CaMKII inhibition in human primary and pluripotent stem cell-derived chondrocytes modulates effects of TGFβ and BMP through SMAD signaling  B. Saitta,
Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia by Shahrzad Jalali, Tammy Price-Troska, Jonas Paludo, Jose Villasboas, Hyo-Jin.
Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia by Xavier Leleu, Lian Xu, Xiaoying Jia, Antonio Sacco, Mena Farag,
SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy
Relative mRNA expression level (/J3T-1)
PD-1 blockade enhances elotuzumab efficacy in mouse tumor models
Volume 25, Issue 3, Pages (March 2017)
Volume 142, Issue 7, Pages e2 (June 2012)
RANK Is Expressed in Metastatic Melanoma and Highly Upregulated on Melanoma- Initiating Cells  Verena Kupas, Carsten Weishaupt, Dorothee Siepmann, Maria-Laura.
by Kamira Maharaj, John J
by Silvia Mele, Stephen Devereux, Andrea G
Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells by Xiaoli Wang, Cing Siang Hu, Bruce Petersen, Jiajing.
VAY-736 combines effectively with ibrutinib in vivo.
MiR-135b Stimulates Osteosarcoma Recurrence and Lung Metastasis via Notch and Wnt/β-Catenin Signaling  Hua Jin, Song Luo, Yun Wang, Chang Liu, Zhenghao.
14-3-3σ Regulates Keratinocyte Proliferation and Differentiation by Modulating Yap1 Cellular Localization  Sumitha A.T. Sambandam, Ramesh B. Kasetti,
Myeloma cell–derived Runx2 promotes myeloma progression in bone
Kruppel-like factor 4 regulates neutrophil activation
Volume 12, Issue 4, Pages (July 2015)
Volume 19, Issue 8, Pages (August 2011)
by Derek Hoi-Hang Ho, and Roger Hoi-Fung Wong
Volume 6, Issue 2, Pages (February 2010)
Volume 17, Issue 2, Pages (February 2009)
Volume 25, Issue 4, Pages (April 2017)
Paradoxical enhancement of leukemogenesis in acute myeloid leukemia with moderately attenuated RUNX1 expressions by Ken Morita, Shintaro Maeda, Kensho.
Twist1 regulates embryonic hematopoietic differentiation through binding to Myb and Gata2 promoter regions by Kasem Kulkeaw, Tomoko Inoue, Tadafumi Iino,
Human hematopoietic stem cell maintenance and myeloid cell development in next-generation humanized mouse models by Trisha R. Sippel, Stefan Radtke, Tayla.
Hypoxia-inducible KDM3A addiction in multiple myeloma
Targeting ubiquitin-activating enzyme induces ER stress–mediated apoptosis in B-cell lymphoma cells by Scott Best, Taylor Hashiguchi, Adam Kittai, Nur.
by Rodrigo Abreu, Frederick Quinn, and Pramod K. Giri
Intratumoral platelet aggregate formation in a murine preclinical glioma model depends on podoplanin expression on tumor cells by Barbara Costa, Tanja.
TFAP2A knockdown inhibits tumor growth in vivo.
Volume 25, Issue 6, Pages (June 2017)
Loss of HDAC3 inhibits CREBBP-mutant lymphoma growth in vitro and in vivo. Loss of HDAC3 inhibits CREBBP-mutant lymphoma growth in vitro and in vivo. A,
Arati Sridharan, Chetan Patel, Jit Muthuswamy 
Volume 15, Issue 2, Pages (February 2007)
Presentation transcript:

Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma by Ilyas Sahin, Yawara Kawano, Romanos Sklavenitis-Pistofidis, Michele Moschetta, Yuji Mishima, Salomon Manier, Antonio Sacco, Ruben Carrasco, Rafael Fonseca, Aldo M. Roccaro, Thomas Witzig, and Irene M. Ghobrial BloodAdv Volume 3(7):995-1002 April 9, 2019 © 2019 by The American Society of Hematology

Ilyas Sahin et al. Blood Adv 2019;3:995-1002 © 2019 by The American Society of Hematology

CIT is highly expressed in MM patients. CIT is highly expressed in MM patients. (A) Significant increase in CIT in primary BM-derived CD138+ MM plasma cells compared with healthy subjects by proteomic analysis using the Antibody Microarray (BD Clontech). (B) CIT gene expression levels in healthy control, newly diagnosed, and relapsed MM patients are shown. (C) Expression of CIT in BM biopsy specimens from MM patients (n = 11) and healthy donors (normal bone marrow [NMB]; n = 6) was detected by immunohistochemistry. Representative slides are shown for each group (original magnification ×20 [left] and ×60 [right]). (D) CIT+ cells in immunohistochemistry-stained slides were quantified using ImageJ software (P = .02). (E) Using CIT median gene expression value as a bifurcating point in GSE2658, Kaplan-Meier survival proportions analysis of patient outcome data demonstrates high levels of CIT gene expression associated with inferior OS (P = .01). Ilyas Sahin et al. Blood Adv 2019;3:995-1002 © 2019 by The American Society of Hematology

CIT silencing decreases MM tumor growth in vitro and induces cytokinesis failure. CIT silencing decreases MM tumor growth in vitro and induces cytokinesis failure. (A) Depletion of CIT induced by shRNA (F5 and F10) in OPM2 and MM.1s cells was validated using qRT-PCR. (B) OPM2 and MM.1s CIT-knockdown cells were cultured for 48 hours. Cell proliferation was measured using [3H]-thymidine uptake assay. CIT silencing led to significant inhibition of MM cell proliferation (P < .001 and P < .02, respectively). (C) Immunofluorescence of OPM2 and MM.1s cells transfected with scramble or CIT shRNA (F5). Green arrows in enlarged images (magnification ×200) of original magnifications (×100) show nuclei; DAPI (blue) and α-tubulin (red). (D) Multinucleated OPM2 cells were quantified by immunofluorescence. Random fields were analyzed. A significant increase in multinucleated cells in short hairpin (sh)–CIT (F5)-knockdown cells was observed compared with scramble control. (E) The cell cycle of CIT-knockdown OPM2 and MM.1s cells was assessed by propidium iodide (PI) staining and flow cytometric analysis. Although silencing of CIT increased the G2-phase population in OPM2 cells, it did not have any effect on the G2-phase population in MM.1s cells. K.D., knockdown; scr/Scr, scramble. Ilyas Sahin et al. Blood Adv 2019;3:995-1002 © 2019 by The American Society of Hematology

CIT knockdown of MM cells reduced tumor growth in vivo. CIT knockdown of MM cells reduced tumor growth in vivo. SCID/Beige mice were injected subcutaneously with OPM2 CIT-knockdown cells (n = 8) or scramble cells (n = 7) (5 × 106 per mouse) to establish an MM xenograft model. Tumor growth was measured, and volume was calculated as (length [mm] × width2 [mm2])/2. (A) CIT-knockdown cells showed reduced tumor growth in vivo (P < .001). (B) Mice bearing CIT-knockdown cells exhibited significantly prolonged survival (P < .001). (C) CIT expression of tumors collected from mice injected with scramble or CIT-knockdown cells. Decrease in CIT expression was confirmed ex vivo on harvested tumors using qRT-PCR. K.D, knockdown; Scr, scramble control. Ilyas Sahin et al. Blood Adv 2019;3:995-1002 © 2019 by The American Society of Hematology

Dependency Map analysis. Dependency Map analysis. (A) CIT-dependency scores for available MM cell lines. (B) Multivariate analysis of CIT and related genes showing TP53 expression as an independent predictor of CIT dependency (multivariate P = .02). Ilyas Sahin et al. Blood Adv 2019;3:995-1002 © 2019 by The American Society of Hematology